G. Demir et al., Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma, INT J IMM T, 14(3), 1998, pp. 163-168
Interleukin-2 (IL-2) is a glycoprotein with significant immune effects. Our
aims in this study were to define the early immune response of low-dose IL
-2 therapy in patients with metastatic malignant melanoma. Ten patients wit
h metastatic malignant melanoma with no prior therapy and 10 healthy person
s as a control group were included in the study. IL-2 (4.5 Mio U/day) was i
njected subcutaneously from day I to day 4 (D1-4) to the patients. It was f
ound that the absolute values of cluster of differentiation (CD)2, CD3, CD4
and CD8 T-cells increased significantly on day 5 (p=0.03, p=0.03, p=0.02,
p=0.003, respectively). CD 16/CD56 positive natural killer cells increased
significantly at h 24 (p=0.008). IL-2 receptor (CD25) expression on CD2 pos
itive, and human leukocyte antigen (HLA)-DR expression on CD3 positive T-ce
lls increased markedly on the 5th day of treatment (p=0.01, p=0.05, respect
ively). Memory T-helper cells (CD4/CD45RO) showed a significant increase on
day 5 (p=0.03). In conclusion, low-dose subcutaneous consecutive-day admin
istration of IL-2 leads to early and effective immunostimulation in patient
s with metastatic melanoma.